Composite metrics in response assessment-new hope in oesophageal cancer?

Affiliations

Editorial

Janusz Włodarczyk et al. J Thorac Dis. 2017 Sep.

. 2017 Sep;9(9):2786-2787.

doi: 10.21037/jtd.2017.08.28.

¹ Department of Thoracic Surgery, Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow, Poland.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Challenges in assessing response of oesophageal cancer to neoadjuvant therapy, and the potential of composite PET-CT and multimodal metrics.
Findlay JM, Bradley KM, Gillies RS, Maynard ND, Middleton MR. Findlay JM, et al. J Thorac Dis. 2017 Oct;9(10):3551-3552. doi: 10.21037/jtd.2017.09.54. J Thorac Dis. 2017. PMID: 29266129 Free PMC article. No abstract available.

Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemotherapy: The Implications of Metabolic Nodal Response for Personalized Therapy.
Findlay JM, Bradley KM, Wang LM, Franklin JM, Teoh EJ, Gleeson FV, Maynard ND, Gillies RS, Middleton MR. Findlay JM, et al. J Nucl Med. 2017 Feb;58(2):266-275. doi: 10.2967/jnumed.116.176313. Epub 2016 Sep 15. J Nucl Med. 2017. PMID: 27635027 Clinical Trial.

1. Shapiro J, van Lanschot JJ, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16:1090-8. 10.1016/S1470-2045(15)00040-6 - DOI - PubMed
1. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84. 10.1056/NEJMoa1112088 - DOI - PubMed
1. Donahue JM, Nichols FC, Li Z, et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 2009;87:392-8; discussion 398-9. 10.1016/j.athoracsur.2008.11.001 - DOI - PMC - PubMed
1. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-65. 10.1200/JCO.2001.19.12.3058 - DOI - PubMed
1. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006;24:4692-8. 10.1200/JCO.2006.06.7801 - DOI - PubMed